JP2022530524A5 - - Google Patents

Info

Publication number
JP2022530524A5
JP2022530524A5 JP2021564298A JP2021564298A JP2022530524A5 JP 2022530524 A5 JP2022530524 A5 JP 2022530524A5 JP 2021564298 A JP2021564298 A JP 2021564298A JP 2021564298 A JP2021564298 A JP 2021564298A JP 2022530524 A5 JP2022530524 A5 JP 2022530524A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
seq
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021564298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530524A (ja
JP7585230B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/030245 external-priority patent/WO2020223221A1/en
Publication of JP2022530524A publication Critical patent/JP2022530524A/ja
Publication of JP2022530524A5 publication Critical patent/JP2022530524A5/ja
Priority to JP2024193434A priority Critical patent/JP7844591B2/ja
Application granted granted Critical
Publication of JP7585230B2 publication Critical patent/JP7585230B2/ja
Priority to JP2026059845A priority patent/JP2026116994A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021564298A 2019-04-29 2020-04-28 バイパラトピックFR-α抗体及びイムノコンジュゲート Active JP7585230B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024193434A JP7844591B2 (ja) 2019-04-29 2024-11-05 バイパラトピックFR-α抗体及びイムノコンジュゲート
JP2026059845A JP2026116994A (ja) 2019-04-29 2026-03-31 バイパラトピックFR-α抗体及びイムノコンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962840297P 2019-04-29 2019-04-29
US62/840,297 2019-04-29
US201962879864P 2019-07-29 2019-07-29
US62/879,864 2019-07-29
PCT/US2020/030245 WO2020223221A1 (en) 2019-04-29 2020-04-28 Biparatopic fr-alpha antibodies and immunoconjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193434A Division JP7844591B2 (ja) 2019-04-29 2024-11-05 バイパラトピックFR-α抗体及びイムノコンジュゲート

Publications (3)

Publication Number Publication Date
JP2022530524A JP2022530524A (ja) 2022-06-29
JP2022530524A5 true JP2022530524A5 (cg-RX-API-DMAC7.html) 2023-05-10
JP7585230B2 JP7585230B2 (ja) 2024-11-18

Family

ID=73028723

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021564298A Active JP7585230B2 (ja) 2019-04-29 2020-04-28 バイパラトピックFR-α抗体及びイムノコンジュゲート
JP2024193434A Active JP7844591B2 (ja) 2019-04-29 2024-11-05 バイパラトピックFR-α抗体及びイムノコンジュゲート
JP2026059845A Pending JP2026116994A (ja) 2019-04-29 2026-03-31 バイパラトピックFR-α抗体及びイムノコンジュゲート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024193434A Active JP7844591B2 (ja) 2019-04-29 2024-11-05 バイパラトピックFR-α抗体及びイムノコンジュゲート
JP2026059845A Pending JP2026116994A (ja) 2019-04-29 2026-03-31 バイパラトピックFR-α抗体及びイムノコンジュゲート

Country Status (12)

Country Link
US (4) US11396543B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962935A4 (cg-RX-API-DMAC7.html)
JP (3) JP7585230B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004687A (cg-RX-API-DMAC7.html)
CN (1) CN114222756A (cg-RX-API-DMAC7.html)
AU (2) AU2020265568B2 (cg-RX-API-DMAC7.html)
CA (1) CA3138272A1 (cg-RX-API-DMAC7.html)
IL (1) IL287451A (cg-RX-API-DMAC7.html)
MA (1) MA55818A (cg-RX-API-DMAC7.html)
SG (1) SG11202111109UA (cg-RX-API-DMAC7.html)
TW (2) TWI872065B (cg-RX-API-DMAC7.html)
WO (1) WO2020223221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2997044A4 (en) * 2013-05-14 2017-03-22 ImmunoGen, Inc. Anti-folr1 immunoconjugate dosing regimens
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
SG11202111109UA (en) 2019-04-29 2021-11-29 Immunogen Inc Biparatopic fr-alpha antibodies and immunoconjugates
US11912781B2 (en) * 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof
WO2022217022A1 (en) * 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
KR20240017024A (ko) * 2021-06-04 2024-02-06 이뮤노젠 아이엔씨 가용성 fr-알파를 이용한 환자의 암 치료
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
TW202409080A (zh) * 2022-07-26 2024-03-01 美商沙塔克實驗室股份有限公司 用於治療卵巢癌之組合療法
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法
US12649790B2 (en) 2023-07-03 2026-06-09 Medicovestor, Inc. Proteins that bind SP17 including fully-human anti-SP17 antibodies
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
US12673991B2 (en) 2023-12-26 2026-07-07 Medicovestor, Inc. Methods of crosslinking IgG
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
CN122535429A (zh) 2024-01-05 2026-08-07 信达生物制药(苏州)有限公司 抗体以及包含其与tlr7/8激动剂的免疫偶联物及其用途
TW202608930A (zh) * 2024-06-05 2026-03-01 大陸商長春金賽藥業有限責任公司 靶向葉酸受體α(FRα)的抗體、雙特異性抗體和偶聯物,及其製備和用途
US20260001950A1 (en) * 2024-07-01 2026-01-01 Medicovestor, Inc. Methods of enhancing efficacy of immunoconjugates using paired human antibodies targeted at non-overlapping b-cell epitopes on the same antigen
US20260078179A1 (en) * 2024-07-18 2026-03-19 Novarock Biotherapeutics, Ltd. Cdh17 antibodies and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
SG189957A1 (en) * 2010-11-05 2013-06-28 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
ES2661466T3 (es) 2011-04-01 2018-04-02 Immunogen, Inc. Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
EP2997044A4 (en) 2013-05-14 2017-03-22 ImmunoGen, Inc. Anti-folr1 immunoconjugate dosing regimens
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
JP6463744B2 (ja) 2013-10-08 2019-02-06 イミュノジェン, インコーポレイテッド 抗folr1免疫抱合体投薬レジメン
US20170247449A1 (en) 2014-06-06 2017-08-31 Kyowa Hakko Kirin Co., Ltd Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism
MA40539A (fr) 2014-09-02 2016-03-10 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicaments
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
IL298414B2 (en) 2017-02-28 2024-12-01 Immunogen Inc Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
GB201707864D0 (en) 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment
JP7604226B2 (ja) 2017-09-05 2024-12-23 イミュノジェン, インコーポレイテッド 患者の試料中のヒト葉酸受容体1を検出するための方法
TWI826393B (zh) 2017-09-22 2023-12-21 美商免疫遺傳股份有限公司 使用陽離子交換層析法分離三輕鏈抗體
AU2019206587A1 (en) 2018-01-12 2020-08-06 Immunogen, Inc. Methods for antibody drug conjugation, purification, and formulation
SG11202111109UA (en) * 2019-04-29 2021-11-29 Immunogen Inc Biparatopic fr-alpha antibodies and immunoconjugates
KR20240017024A (ko) * 2021-06-04 2024-02-06 이뮤노젠 아이엔씨 가용성 fr-알파를 이용한 환자의 암 치료

Similar Documents

Publication Publication Date Title
US20230138930A1 (en) Tissue factor-targeted antibody-drug conjugate
US20240173427A1 (en) Glypican 3 antibodies and conjugates thereof
TWI872065B (zh) 雙互補位FR-α抗體及免疫結合物
US20230173093A1 (en) Charge variant linkers
CN105451775B (zh) 药物抗体缀合物
RU2765098C2 (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
US10618935B2 (en) Antibody-drug conjugate (ADC) and method for forming the same
CN110240654A (zh) 结合cd73的抗体-药物偶联物
JP2018524373A5 (cg-RX-API-DMAC7.html)
US12006370B2 (en) Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
CN102065891A (zh) 新型协同效应
JP2023504187A5 (cg-RX-API-DMAC7.html)
JP2021528471A5 (cg-RX-API-DMAC7.html)
CN107614488A (zh) 新型亲水连接体和其在配体‑药物共轭偶联物上的应用
US20210260212A1 (en) Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy
CN120835792A (zh) 抗体-药物偶联物靶向治疗前列腺癌和其他肿瘤
WO2023098691A1 (zh) 抗体药物偶联物及其用途
CN115052663A (zh) Alk5抑制剂缀合物及其用途
IL273384B2 (en) Methods of preventing methionine oxidation in immunoconjugates
CN119156231A (zh) 提高鹅膏蕈毒素-抗体缀合物的治疗指数的方法
JP2024532677A5 (cg-RX-API-DMAC7.html)
RU2021130453A (ru) Бипаратопные fr-альфа антитела и иммуноконъюгаты
RU2023100251A (ru) Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство
RU2021104563A (ru) Конъюгаты антитело-лекарственное средство и их применение